Spalbort 3,5 Mg 3,5 mg Lyophilised powder for solution for injection
PDF Leaflet Revision Date: 8 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and relapsed mantle cell lymphoma.
Dosage (summary)
1.3 mg/mu00b2 twice weekly for 2 weeks, then rest; adjust for toxicity.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not established; avoid breastfeeding during treatment.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Oral hypoglycemics
Contraindications
- Hypersensitivity to bortezomib
- Severe hepatic impairment
- Acute pulmonary disease
Common side effects
- Thrombocytopaenia
- Neuropathy
- Nausea
- Fatigue
Counselling Points
- Use effective contraception
- Monitor for signs of neuropathy
- Report severe side effects immediately
Serious warnings
- Do not administer intrathecally
- Risk of herpes zoster reactivation
- Monitor for PML
Important Disclaimer
The Spalbort 3,5 Mg 3,5 mg Lyophilised powder for solution for injection professional information leaflet below is the property of Ruby Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
